Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

blockbuster type 2 diabetes and weight loss drug tirzepatide was no longer in shortage. Despite closing the case, however, the FDA said it is "carefully assessing the challenged decision and ...

Novo Nordisk and Eli Lilly are moving to end compounding of their medicines for good. They say they are no longer in shortage ...

Eli Lilly and rival Novo Nordisk have been testing their drugs for conditions beyond obesity and diabetes. The U.S. Food and Drug Administration is set to decide on the use of Lilly's weight-loss ...

In an unconventional push to expand coverage for weight loss medications, Eli Lilly representatives recently visited the New Jersey State Policemen's Benevolent Association to promote their drug ...

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau ... That's unlike Eli Lilly's obesity drug, Zepbound ...

The treatment demonstrates the diversity of Eli Lilly's drug pipeline beyond its top-selling weight loss and diabetes treatments ... There are currently no approved treatments to lower Lp ...

Weight loss benefits from Amgen's monthly injection MariTide miss investor expectations MariTide's trial results comparable to Novo Nordisk and Eli Lilly ... drug The mid-stage study also showed ...